A multi-targeted RTK inhibitor
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
Amuvatinib is a multi-targeted inhibitor of receptor tyrosine kinases that inhibits c-Kit, platelet-derived growth factor receptor α (PDGFRα), and c-Met (IC50s = 10, 40, and 81 nM, respectively).1 It inhibits growth and induces apoptosis in prostate cancer cell lines, with additive effects achieved when combined with erlotinib .1 Amuvatinib sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination.2,3,4
1.Qi, W., Cooke, L.S., Stejskal, A., et al.MP470, a novel receptor tyrosine kinase inhibitor, in combination with erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerBMC Cancer9(142)1-12(2009) 2.Padda, S., Neal, J.W., and Wakelee, H.A.MET inhibitors in combination with other therapies in non-small cell lung cancerTransl. Lung Cancer Res.1(4)238-253(2012) 3.Welsh, J.W., Mahadevan, D., Ellsworth, R., et al.The c-Metreceptortyrosine kinaseinhibitor MP470 radiosensitizes glioblastomacellsRadiat. Oncol.4(69)(2009) 4.Zhao, H., Luoto, K.R., Meng, A.X., et al.The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombinationRadiother. Oncol.101(1)59-65(2011)
Motesanib Diphosphate (AMG-706)
¥350.00 ¥437.00
Cediranib maleate (AZD-2171 maleate)
¥440.00 ¥550.00
没有评价数据